𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Weight-loss associated with anti-dementia drugs in a patient with Parkinson's disease

✍ Scribed by Adeline Gallini; Agnès Sommet; Anne-Marie Salandini; Patrick Veyssière; Jean-Louis Montastruc; Jean-Louis Montastruc

Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
45 KB
Volume
22
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Body weight in patients with Parkinson's
Body weight in patients with Parkinson's disease
✍ Cornelius G. Bachmann; Claudia Trenkwalder 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 75 KB 👁 1 views

## Abstract There is some evidence suggesting that Parkinson's disease (PD) patients exhibit lower body weight when compared to age‐matched healthy subjects. Low body mass index (BMI) is correlated with low bone mineral density, both of which are major risk factors for hip fractures. Possible deter

Measuring the effects of anti-dementia d
Measuring the effects of anti-dementia drugs in patients with Alzheimer's disease
✍ S. Curran; J. P. Wattis 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 179 KB 👁 2 views

A large number of experimental compounds are being developed for the treatment of patients with Alzheimer's disease (AD). As dierent compounds may have dierent eects on CNS function, depending on which neurotransmitters they aect, adequate pro®ling will require the use of several tests. The dicultie

Hyperhomocysteinemia in levodopa-treated
Hyperhomocysteinemia in levodopa-treated patients with Parkinson's disease dementia
✍ Stefano Zoccolella; Claudia dell'Aquila; Giovanni Abruzzese; Angelo Antonini; Ub 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB

## Abstract Dementia is a frequent non‐motor feature of Parkinson's disease (PD). Elevated plasma homocysteine (Hcy) levels have been associated with both cognitive impairment and dementia. Increased Hcy levels have been observed in levodopa‐treated patients with PD. The objective of our study was